These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 2478179)
1. Prednisolone enhancement of primary endocrine anticancer treatment: a possible anti-angiogenic effect. Beranek JT Br J Cancer; 1989 Jul; 60(1):149. PubMed ID: 2478179 [No Abstract] [Full Text] [Related]
2. Novel strategies towards the use of anti-angiogenic agents in breast cancer. Bakker JL; Meijers-Heijboer H; Verheul H Eur J Pharmacol; 2013 Oct; 717(1-3):36-9. PubMed ID: 23545363 [TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives. Aalders KC; Tryfonidis K; Senkus E; Cardoso F Cancer Treat Rev; 2017 Feb; 53():98-110. PubMed ID: 28088074 [TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells. Atmaca H; Uzunoglu S Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346 [TBL] [Abstract][Full Text] [Related]
5. Breast tumour angiogenesis. Fox SB; Generali DG; Harris AL Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723 [TBL] [Abstract][Full Text] [Related]
6. Laminin isoform expression in breast tumors. Holler E Breast Cancer Res; 2005; 7(4):166-7. PubMed ID: 15987470 [TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. Banciu M; Schiffelers RM; Fens MH; Metselaar JM; Storm G J Control Release; 2006 Jun; 113(1):1-8. PubMed ID: 16707187 [TBL] [Abstract][Full Text] [Related]
8. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Stambolic V; Woodgett JR; Fantus IG; Pritchard KI; Goodwin PJ Breast Cancer Res Treat; 2009 Mar; 114(2):387-9. PubMed ID: 18438706 [No Abstract] [Full Text] [Related]
9. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Rubens RD; Tinson CL; Coleman RE; Knight RK; Tong D; Winter PJ; North WR Br J Cancer; 1988 Nov; 58(5):626-30. PubMed ID: 3219274 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Hadad SM; Appleyard V; Thompson AM Breast Cancer Res Treat; 2009 Mar; 114(2):391. PubMed ID: 18421577 [No Abstract] [Full Text] [Related]
11. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Boudreau N; Myers C Breast Cancer Res; 2003; 5(3):140-6. PubMed ID: 12793895 [TBL] [Abstract][Full Text] [Related]
12. Prednisolone in terminal breast and bronchogenic cancer. Twycross RG; Guppy D Practitioner; 1985 Jan; 229(1399):57-9. PubMed ID: 2581241 [No Abstract] [Full Text] [Related]
13. A randomized clinical trial to investigate the usefulness of the addition of prednisolone to tamoxifen as adjuvants to mastectomy in primary breast cancer patients with a high risk of recurrence: a preliminary report. DiMartino L; Demontis B; Mitchell IP; Hayward SW; Deshpande N Anticancer Res; 1991; 11(2):869-72. PubMed ID: 2064345 [TBL] [Abstract][Full Text] [Related]
14. [Combined leukeran-prednisolone therapy in metastasizing breast cancer]. Cziráki L; Oó M Fortschr Med; 1977 Apr; 95(15):1043-6. PubMed ID: 858580 [No Abstract] [Full Text] [Related]
15. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer: the role of angiogenesis and antiangiogenic therapy. Miller KD; Dul CL Hematol Oncol Clin North Am; 2004 Oct; 18(5):1071-86, ix. PubMed ID: 15474336 [TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Hayot C; Farinelle S; De Decker R; Decaestecker C; Darro F; Kiss R; Van Damme M Int J Oncol; 2002 Aug; 21(2):417-25. PubMed ID: 12118340 [TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic agents in breast cancer. Salter JT; Miller KD Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149 [No Abstract] [Full Text] [Related]
19. A pilot study of sequential combination chemotherapy with adriamycin and cyclophosphamide, and methotrexate, 5-fluorouracil and prednisolone in advanced breast cancer. Collis CH Br J Clin Pract; 1978 May; 32(5):139-44. PubMed ID: 666968 [No Abstract] [Full Text] [Related]
20. Effect of prednisolone on hormone profiles during primary endocrine treatment of advanced breast cancer. Blackburn AM; Wang DY; Bulbrook RD; Thomas BS; Kwa HG; Hoare SA; Rubens RD Cancer Treat Rep; 1984 Dec; 68(12):1447-53. PubMed ID: 6239689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]